On Monday, Galena Biopharma Inc (NASDAQ:GALE)’s shares declined -1.43% to $1.38.
Galena Biopharma Inc (GALE) declared the completion of enrollment in the NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial. NeuVax(TM) is a first-in-class, HER2-directed cancer immunotherapy under evaluation to prevent breast cancer recurrence after standard of care treatment in the adjuvant setting.
As anticipated, Galena over-enrolled the trial by 7.7% with a total of 758 patients now in the intent-to-treat (ITT) population. The protocol for the PRESENT trial, being conducted under an FDA approved Special Protocol Assessment (SPA), called for 700 patients; and, the Company anticipates this higher number of ITT patients will raise the confidence in both the timing and quality of the statistics and the final outcome of the trial. The primary endpoint is presently predictable to be reached in 2018, after the last patient dosed reaches her 36th month of treatment, or a total of 141 events (recurrence or death) occur, whichever comes later.
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology therapeutics that address major unmet medical needs across cancer care.
Rowan Companies PLC (NYSE:RDC)’s shares dropped -1.43% to $20.03.
Rowan Companies PLC (RDC) plans to report earnings for the three months ended March 31, 2015 on Wednesday, May 6, 2015, before the open of the financial markets in the United States. Following the earnings report, the Company will conduct a conference call at 10:00 a.m. Central Daylight Time to talk about its operating results. Interested parties can listen to the conference call by telephone or over the internet.
Rowan Companies plc provides offshore oil and gas contract drilling services. It operates a fleet of 30 self-elevating mobile offshore jack-up drilling units, in addition to 3 ultra-deepwater drill ships.
At the end of Monday’s trade, McEwen Mining Inc (NYSE:MUX)‘s shares dipped -1.37% to $0.970.
McEwen Mining Inc (MUX) reports gold production raised 23% and silver production reduced 10% in Q1 2015 vs Q1 2014. Gold and silver recoveries were artificially low as a result of the recent gold theft and will return to normal in Q2. Production costs for Q1 2015 will be stated with the quarterly financial results in early May 2015.
Guidance for 2015 production remains unchanged at 96,500 gold ounces and 3.1 million silver ounces.
McEwen Mining Inc. explores for, develops, produces, and sells precious and base metals in Argentina, Mexico, and the United States. It primarily explores for gold, silver, and copper.
Precision Drilling Corp (USA) (NYSE:PDS), ended its Monday’s trading session with -1.42% loss, and closed at $6.94.
Precision Drilling Corp (USA) (PDS) intends to release its 2015 first quarter results before the market opens on Monday, April 27, 2015 and has planned a conference call and webcast to start promptly at 12:00 Noon MT (2:00 p.m. ET) on the same day.
Precision Drilling Corporation provides oil and natural gas drilling and related services and products. The company operates through two segments, Contract Drilling Services; and Completion and Production Services. The Contract Drilling Services segment offers onshore well drilling services to exploration and production companies in the oil and natural gas industry.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
